Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 690517 in Healthy Chinese and Japanese Male Subjects (Double-blind, Randomised, Placebo-controlled Group Design)
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2018
At a glance
- Drugs BI 690517 (Primary)
- Indications Diabetic neuropathies
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 10 Oct 2017 Status changed from recruiting to completed.
- 02 Oct 2017 Planned End Date changed from 2 Oct 2017 to 3 Oct 2017.
- 02 Oct 2017 Planned primary completion date changed from 2 Oct 2017 to 3 Oct 2017.